Precision BioSciences, Inc.
Azer-Cel
Diffuse Large B-Cell Lymphoma
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews Azer-Cel for Diffuse Large B-Cell Lymphoma around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 12h ago
“Imugene’s recent FDA discussions have reached clear alignment across key elements required to advance azer-cel into a pivotal study including dosing regimen, patient population, endpoints, and manufacturing readiness.”